Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Chief Operating Officer | October 02, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date October 02, 2026 · Filed October 07, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 89,602 |
Last balance in matching sequence
After 2026-10-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-10-05 · Sale · Disposed 30 · Balance 89,928 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2: The original Form 4 inadvertently overstated the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. This amendment correctly states the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-10-05 · Sale · Disposed 326 · Balance 89,602 F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025. F2: The original Form 4 inadvertently overstated the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. This amendment correctly states the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2: The original Form 4 inadvertently overstated the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. This amendment correctly states the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 22:24 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 326 | $3.78 | $1,232.28 |
DisclosureSEC source: 0002119908-26-000013 · form4a-10072026_101043.xml · nonDerivative · entry 2 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,602 F4 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025. F2 · balance_after: The original Form 4 inadvertently overstated the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. This amendment correctly states the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 22:24 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 30 | $3.57 | $107.10 |
DisclosureSEC source: 0002119908-26-000013 · form4a-10072026_101043.xml · nonDerivative · entry 1 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,928 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · shares: The original Form 4 inadvertently overstated the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. This amendment correctly states the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. F2 · price: The original Form 4 inadvertently overstated the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. This amendment correctly states the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: The original Form 4 inadvertently overstated the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. This amendment correctly states the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 326 | $3.78 | $1,232.28 |
DisclosureSEC source: 0002119908-26-000011 · form4-10062026_041004.xml · nonDerivative · entry 3 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,552 F4 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 80 | $3.56 | $284.80 |
DisclosureSEC source: 0002119908-26-000011 · form4-10062026_041004.xml · nonDerivative · entry 2 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,878 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,094 | $3.47 | $3,796.18 |
DisclosureSEC source: 0002119908-26-000011 · form4-10062026_041004.xml · nonDerivative · entry 1 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,958 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0002119908-26-000009 · form4-07172026_040701.xml · derivative · entry 1 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2036-07-15 F1 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on July 15, 2027 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 21:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 333 | $4.34 | $1,445.22 |
DisclosureSEC source: 0002119908-26-000007 · form4-07072026_050711.xml · nonDerivative · entry 3 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,052 F4 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 21:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 43 | $4.31 | $185.33 |
DisclosureSEC source: 0002119908-26-000007 · form4-07072026_050711.xml · nonDerivative · entry 2 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,385 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.31 inclusive. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 21:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,036 | $4.27 | $4,423.72 |
DisclosureSEC source: 0002119908-26-000007 · form4-07072026_050711.xml · nonDerivative · entry 1 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,428 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| April 06, 2026 Filed Apr 6, 2026 22:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 333 | $5.04 | $1,678.32 |
DisclosureSEC source: 0002119908-26-000005 · form4-04062026_060405.xml · nonDerivative · entry 3 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,464 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.035 to $5.04 inclusive. Read SEC document |
| April 06, 2026 Filed Apr 6, 2026 22:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 37 | $5.05 | $186.85 |
DisclosureSEC source: 0002119908-26-000005 · form4-04062026_060405.xml · nonDerivative · entry 2 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,797 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 22:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,038 | $4.91 | $5,096.58 |
DisclosureSEC source: 0002119908-26-000005 · form4-04062026_060405.xml · nonDerivative · entry 1 Perry Jennifer Scott · CIK 0002119908 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,834 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.88 to $4.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.